gfb-887
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2019 (NCT03970122)
Timeline
Indications
Studied for
- Diabetes Complications · Phase 2
- Diabetes Mellitus · Phase 2
- Diabetic Nephropathies · Phase 2
- Endocrine System Diseases · Phase 2
- Glomerulonephritis · Phase 2
- Glomerulosclerosis, Focal Segmental · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Diseases · Phase 2
- Mental Disorders · Phase 2
- Nephritis · Phase 2
- Nephrosis · Phase 2
- Nephrosis, Lipoid · Phase 2
- Sclerosis · Phase 2
- Urological Manifestations · Phase 2
- Urologic Diseases · Phase 2
Mechanism of action
TRPC5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04950114 | Phase 2 | Jul 27, 2021 | Goldfinch Bio, Inc. |
| NCT04387448 | Phase 2 | May 31, 2020 | Goldfinch Bio, Inc. |
| NCT03970122 | Phase 1 | May 29, 2019 | Covance, Goldfinch Bio, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Goldfinch Bio, Inc. | For profit | 3 | 3 | 2 | 2019 |
| Covance | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1